Array BioPharma (ARRY) Posts Mixed Q3 Results
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.96 -6.6%
EPS Growth %: -70.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -70.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Array BioPharma, Inc. (Nasdaq: ARRY) reported Q3 loss of $0.20, $0.05 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $17.8 million versus the consensus estimate of $19.58 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades Array Technologies (ARRY) to Neutral
- Radiant Logistics (RLGT) Tops Q4 EPS by 9c
- Macy's (M) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
